バトクリマブ市場：市場規模、予測、新たな洞察- 2032年

Immunovantの最初の治験薬であるバトクリマブ（IMVT-1401）は、新生児Fc受容体（FcRn）を標的とする新規の完全ヒト型モノクローナル抗体です。非臨床試験および臨床試験において、バトクリマブはIgG抗体レベルを低下させることが確認されています。高濃度の病原性IgG抗体は様々な自己免疫疾患の原動力であり、その結果、この製品候補は自己皮下注射剤として様々なIgGを介する自己免疫疾患に対処できる可能性があります。

新生児Fcレセプター（FcRn）は、IgG抗体と結合し、その細胞内輸送を誘導する細胞レセプターです。FcRnはIgG抗体の分解を防ぐ上で極めて重要な役割を果たしています。したがって、FcRnを標的とする抗体でFcRnを阻害すると、病原性IgG抗体のレベルが低下することが示されています。IgGを介する自己免疫疾患における他の抗FcRn抗体の臨床試験が完了し、有望な結果が得られていることから、FcRnはこれらの関連する病態を治療するための治療上重要な医薬ターゲットであることが示唆されています。

今後数年間で、バセドウ病眼症の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病態を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、バトクリマブの優位性に影響を与える可能性のある機会を模索しています。バセドウ病眼症に対する他の新興製品がバトクリマブとの厳しい市場競争をもたらすと予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるバセドウ病眼症治療薬のXADAGO市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 バセドウ病眼症におけるバトクリマブの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 バトクリマブ市場評価

• バセドウ病眼症におけるバトクリマブ市場の見通し
• 主要7ヶ国分析
  • 主要7ヶ国のバセドウ病眼症におけるバトクリマブ市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Batoclimab, Clinical Trial Description, 2023
• Table 2: Batoclimab, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: Batoclimab Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Batoclimab Market Size in the US, in USD million (2019-2032)
• Table 7: Batoclimab Market Size in Germany, in USD million (2019-2032)
• Table 8: Batoclimab Market Size in France, in USD million (2019-2032)
• Table 9: Batoclimab Market Size in Italy, in USD million (2019-2032)
• Table 10: Batoclimab Market Size in Spain, in USD million (2019-2032)
• Table 11: Batoclimab Market Size in the UK, in USD million (2019-2032)
• Table 12: Batoclimab Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Batoclimab Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Batoclimab Market Size in the United States, USD million (2019-2032)
• Figure 3: Batoclimab Market Size in Germany, USD million (2019-2032)
• Figure 4: Batoclimab Market Size in France, USD million (2019-2032)
• Figure 5: Batoclimab Market Size in Italy, USD million (2019-2032)
• Figure 6: Batoclimab Market Size in Spain, USD million (2019-2032)
• Figure 7: Batoclimab Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Batoclimab Market Size in Japan, USD million (2019-2032)

"Batoclimab Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about batoclimab for Graves' Ophthalmopathy in the seven major markets. A detailed picture of the batoclimab for Graves' Ophthalmopathy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the batoclimab for Graves' Ophthalmopathy. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the batoclimab market forecast analysis for Graves' Ophthalmopathy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Graves' Ophthalmopathy.

Drug Summary:

Immunovant's first investigational product, batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). In nonclinical studies and clinical trials, batoclimab has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases, and, as a result, this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered subcutaneous injection.

The neonatal Fc receptor (FcRn) is a cellular receptor that binds IgG antibodies and guides their transport through cells. FcRn plays a pivotal role in preventing the degradation of IgG antibodies. Therefore, inhibition of FcRn with an FcRn targeting antibody has been shown to reduce levels of pathogenic IgG antibodies. Completed clinical trials of other anti-FcRn antibodies in IgG-mediated autoimmune diseases have generated promising results, suggesting that FcRn is a therapeutically important pharmaceutical target to treat these relevant pathogenic conditions.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the batoclimab description, mechanism of action, dosage and administration, research and development activities in Graves' Ophthalmopathy.
• Elaborated details on batoclimab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the batoclimab research and development activities in Graves' Ophthalmopathy across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around batoclimab.
• The report contains forecasted sales of batoclimab for Graves' Ophthalmopathy till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Graves' Ophthalmopathy.
• The report also features the SWOT analysis with analyst views for batoclimab in Graves' Ophthalmopathy.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Batoclimab Analytical Perspective by DelveInsight

• In-depth Batoclimab Market Assessment

This report provides a detailed market assessment of batoclimab for Graves' Ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• Batoclimab Clinical Assessment

The report provides the clinical trials information of batoclimab for Graves' Ophthalmopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Graves' Ophthalmopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence batoclimab dominance.
• Other emerging products for Graves' Ophthalmopathy are expected to give tough market competition to batoclimab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of batoclimab in Graves' Ophthalmopathy.
• Our in-depth analysis of the forecasted sales data of batoclimab from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the batoclimab in Graves' Ophthalmopathy.

Key Questions:

• What is the product type, route of administration and mechanism of action of batoclimab?
• What is the clinical trial status of the study related to batoclimab in Graves' Ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the batoclimab development?
• What are the key designations that have been granted to batoclimab for Graves' Ophthalmopathy?
• What is the forecasted market scenario of batoclimab for Graves' Ophthalmopathy?
• What are the forecasted sales of batoclimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to batoclimab for Graves' Ophthalmopathy?
• Which are the late-stage emerging therapies under development for the treatment of Graves' Ophthalmopathy?

Table of Contents

1. Report Introduction

2. Batoclimab Overview in Graves' Ophthalmopathy

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Batoclimab Market Assessment

• 5.1. Market Outlook of Batoclimab in Graves' Ophthalmopathy
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Batoclimab in the 7MM for Graves' Ophthalmopathy
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Batoclimab in the United States for Graves' Ophthalmopathy
  • 5.3.2. Market Size of Batoclimab in Germany for Graves' Ophthalmopathy
  • 5.3.3. Market Size of Batoclimab in France for Graves' Ophthalmopathy
  • 5.3.4. Market Size of Batoclimab in Italy for Graves' Ophthalmopathy
  • 5.3.5. Market Size of Batoclimab in Spain for Graves' Ophthalmopathy
  • 5.3.6. Market Size of Batoclimab in the United Kingdom for Graves' Ophthalmopathy
  • 5.3.7. Market Size of Batoclimab in Japan for Graves' Ophthalmopathy

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options